TRPV3 | Transient Receptor Potential Cation Channel Subfamily V Member 3
Family:
Transient receptor potential channels
Subgroups:
TRPC (TRPC1–TRPC7), TRPV (TRPV1-TRPV6), TRPA1, TRPM (TRPM1–TRPM8), TRPP (TRPP1–TRPP3, PKD1, PKDREJ, PKDL1–PKDL3), TRPML (TRPML1–TRPML3), TRPN
Topology:
Most TRP channels are composed of 6 transmembrane domains (helices) with intracellular N- and C-termini, non-selectively permeable to various cations
TRPV3: Background information
TRPV3 is a putative receptor-activated non-selective calcium permeant cation channel. It is activated by innocuous (22°C - 40°C) temperatures and shows an increased response at noxious temperatures greater than 39 degrees Celsius. Activation exhibits an outward rectification.
Gene:
TRPV3
Human Protein:
UniProt Q8NET8
Tissue:
Widely expressed in the human body, abundantly expressed in the CNS, keratinocyte layers of the outer root sheath and matrix of the hair follicles
Function/ Application:
TRPV3 plays a role in a variety of processes, including temperature sensation and vasoregulation. TRPV3 is a negative regulator of hair growth and cycling: TRPV3-coupled signaling suppresses keratinocyte proliferation in hair follicles and induces apoptosis and premature hair follicle regression (catagen)
Pathology:
Olmsted syndrome (OLMS), Palmoplantar keratoderma, non-epidermolytic, focal 2 (FNEPPK2).
Selective TRPV3 inhibition is being investigated for therapeutic potential for treatment of chronic pruritus, skin allergy, or inflammation-related skin diseases.
Interaction:
TRPV3 may form a heteromeric channel with TRPV1, and it interacts with Calmodulin, epidermal growth factor receptor, AKAP79 (AKAP-5)
Modulator:
Carvacrol, thymol, eugenol, camphor, 2-APB, isopentenyl diphosphate, aspirin-triggered resolvin D1, forsythoside B, isopentenyl diphosphate, osthole, ruthenium red
Assays:
Patch Clamp: whole cell, temperature control
Recommended Reviews:International Union of Pharmacology. XLIII. Compendium of voltage-gated ion channels: transient receptor potential channels., Pharmacol Rev 55(4):591-6 Clapham, et al. 2003